American Journal of Medical Genetics Part B Neuropsychiatric Genetics · 2006 · 60 citations · 23 references
MedicineGeneticsPsychiatryNeurogeneticsPharmacogeneticsPharmacogenomicsAttention-deficit/hyperactivity DisorderNeurodevelopmental DisordersPharmacogenetic TestingPsychiatric GeneticsPsychopharmacology In ChildrenStimulant TherapyAdhd GeneticsAdhd TreatmentAttention-deficit/hyperactivity Disorder GeneticsDopaminergic PathwaysMethylphenidate TherapyOutcome MeasuresPediatric Stimulant TreatmentPharmacogenetics Of Stimulant Response
Few studies on pharmacogenetics of Attention-Deficit/Hyperactivity Disorder (ADHD) have been conducted. Most of them evaluated dopaminergic genes resulting in positive and negative findings. We assessed effects of polymorphisms in candidate dopaminergic (DRD4, DAT1) and serotonergic genes (HTR1B, HTR2A, and 5-HTT) on the response to treatment in 111 patients for whom methylphenidate (MPH) was prescribed. Outcome measures (Swanson, Nolan, and Pelham scale-version IV, Children Global Assessment Scale, Barkley's Stimulants Side Effects Rating Scale) were assessed at baseline and 1 month after the intervention. No significant association was detected between polymorphisms assessed and both response and side effects to MPH. Prospective multi-site controlled studies with larger sample sizes are needed in order to disentangle the role of candidate genes in response to ADHD treatment.
23
A Children's Global Assessment Scale (CGAS)
David Shaffer · Archives of General Psychiatry · 1983 · 3.7K citations
Allelic Variation of Human Serotonin Transporter Gene Expression
Armin Heils, Andreas Teufel, Susanne Petri et al. · Journal of Neurochemistry · 1996 · 2.2K citations